bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

sponsorType

authorLocations

authors

paywallTypes

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

factSheets

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

copyrighted

customTimezone

liveContents

Echo Xie

The Chinese authorities have given conditional approval for the general public use of a Covid-19 vaccine developed by Sinovac Biotech, the company said on Saturday.
The approval is based on results from two months’ worth of phase three clinical trials overseas. However, it said the final analysis data has not yet been obtained and the efficacy and safety results have to be further confirmed.
CoronaVac will be the second Covid-19 vaccine approved for public use in China, after one developed by the state-owned Sinopharm was approved in December.
The firm had officially filed for conditional approval with the National Medical Products Administration on Wednesday.
The move came a day after the company released data from trials in Brazil, Turkey, Indonesia and Chile, which started in July.
A total of 25,000 participants took part in trials across those four countries.
Cambodia becomes latest to sign up for Chinese coronavirus vaccines
As of December CoronaVac was 50.4 per cent effective for preventing mild cases and 83.7 per cent effective for cases requiring medical treatment, according to late-stage trials involving 12,396 Brazilian health workers, the company said.
It showed a 91.25 per cent efficacy based on an interim analysis of 29 cases in Turkey.
Sinovac’s chairman Yin Weidong said in a statement the approval “marks significant progress in tackling Covid-19.”


He added: “We look forward to providing more safe and effective vaccines and ultimately controlling the disease by increasing the vaccination rate, and letting our society and economy get back to normal.”
The company is opening a second production line for the vaccine later this month, which will double its capacity to a billion doses a year.


‘Promising’ steps to HIV vaccine, Trump tariffs threaten Chinese profits: 5 biotech stories

Philippine cockfighting still soars even as feathers are ruffled over job losses

Pragmatic Southeast Asia will adapt to Trump’s ‘America first’ agenda

China-Canada direct flights to ‘surge’ to meet demand as talks yield results

Coronavirus pandemic

Covid-19: China approves Sinovac vaccine for general public use

The Sinovac product has been tested overseas. Photo: Bloomberg

News

China

Science

Coronavirus

Greater China

Health & Medicine


The drug maker said Coronavac had been given the green light based on phase three trial data, even though the final results are not yet available
It will be the second Chinese-made vaccine approved for general use after a drug made by Sinopharm



Covid-19: China approves Sinovac vaccine for general public use

The drug maker said Coronavac had been given the green light based on phase three trial data, even though the final results are not yet available It will be the second Chinese-made vaccine approved for general use after a drug made by Sinopharm

The drug maker said Coronavac had been given the green light based on phase three trial data, even though the final results are not yet available

It will be the second Chinese-made vaccine approved for general use after a drug made by Sinopharm